Page 39 - Demo

www.psypharma.ru %u0421%u043e%u0432%u0440%u0435%u043c%u0435%u043d%u043d%u0430%u044f %u0442%u0435%u0440%u0430 %u043f%u0438%u044f %u043f%u0441%u0438%u0445%u0438%u0447%u0435%u0441%u043a%u0438%u0445 %u0440%u0430 %u0441%u0441%u0442%u0440%u043e%u0439%u0441%u0442%u0432 %u2116 4/2024%u0421%u043e%u0441%u0438%u043d %u0414.%u041d., %u0425%u0430%u0441%u0430%u043d%u043e%u0432%u0430 %u0410.%u041a. %u0438 %u0434%u0440.39%u041e%u0411%u0429%u0418%u0415 %u0412O%u041f%u0420%u041e%u0421%u042b %u0422%u0415%u0420%u0410%u041f%u0418%u0418 %u0418 %u041e%u0411%u0417%u041e%u0420%u042b12. Osborne I.J., McIvor R.J. Clozapine-induced myoclonus: A case report and review of the literature // Ther Adv Psychopharmacol. %u2013 2015. %u2013 Vol. 5 (6). %u2013 P%u0440. 351%u2013356. %u2013 https://doi.org/10.1177/204512531561201512. Osborne I.J., McIvor R.J. Clozapine-induced myoclonus: A case report and review of the literature // Ther Adv Psychopharmacol. %u2013 2015. %u2013 Vol. 5 (6). %u2013 P%u0440. 351%u2013356. %u2013 https://doi.org/10.1177/204512531561201513. Shirazi A., Stubbs B., Gomez L. et al. Prevalence and predictors of clozapine-associated constipation: A systematic review and meta-analysis // Int J Mol Sci. %u2013 2016. %u2013 Vol. 17 (6). %u2013 Art. 863. %u2013 https://doi.org/10.3390/ijms1706086313. Shirazi A., Stubbs B., Gomez L. et al. Prevalence and predictors of clozapine-associated constipation: A systematic review and meta-analysis // Int J Mol Sci. %u2013 2016. %u2013 Vol. 17 (6). %u2013 Art. 863. %u2013 https://doi.org/10.3390/ijms1706086314. Verdoux H., Quiles C., Bachmann C.J., Siskind D. Prescriber and institutional barriers and facilitators of clozapine use: A systematic review // Schizophr Res. %u2013 2018. %u2013 Vol. 201. %u2013P%u0440. 10%u201319. %u2013 https://doi.org/10.1016/j.schres.2018.05.04614. Verdoux H., Quiles C., Bachmann C.J., Siskind D. Prescriber and institutional barriers and facilitators of clozapine use: A systematic review // Schizophr Res. %u2013 2018. %u2013 Vol. 201. %u2013P%u0440. 10%u201319. %u2013 https://doi.org/10.1016/j.schres.2018.05.04615. Lappin J.M., Wijaya M., Watkins A., et al. Cardio-metabolic risk and its management in a cohort of clozapine-treated outpatients // Schizophr Res. %u2013 2018. %u2013 Vol. 199. %u2013 P%u0440. 367%u2013373. %u2013 https://doi.org/10.1016/j.schres.2018.02.03515. Lappin J.M., Wijaya M., Watkins A., et al. Cardio-metabolic risk and its management in a cohort of clozapine-treated outpatients // Schizophr Res. %u2013 2018. %u2013 Vol. 199. %u2013 P%u0440. 367%u2013373. %u2013 https://doi.org/10.1016/j.schres.2018.02.03516. Henderson D.C. Weight gain with atypical antipsychotics: evidence and insights // J ClinPsychiatry. %u2013 2007. %u2013 Vol. 68, suppl. 1. %u2013 P%u0440. 18%u201326.16. Henderson D.C. Weight gain with atypical antipsychotics: evidence and insights // J ClinPsychiatry. %u2013 2007. %u2013 Vol. 68, suppl. 1. %u2013 P%u0440. 18%u201326.17. De Hert M., Detraux J., Winkel R. et al. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs // Nat Rev Endocrinol. %u2013 2012. %u2013 Vol. 8 (2). %u2013P%u0440. 114%u2013126. %u2013 https://doi.org/10.1038/nrendo.2011.15617. De Hert M., Detraux J., Winkel R., et al. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs // Nat Rev Endocrinol. %u2013 2012. %u2013 Vol. 8 (2). %u2013P%u0440 114%u2013126. %u2013 https://doi.org/10.1038/nrendo.2011.15618. Rojas E., Ana Castro A., Manzano A. et al. Diagnostic criteria and management of metabolic syndrome: Evolution overtime // Gac Med Caracas. %u2013 2020. %u2013 Vol. 128 (4). %u2013P%u0440. 480%u2013504. %u2013 http://dx.doi.org/10.47307/GMC.2020.128.4.518. Rojas E., Ana Castro A., Manzano A. et al. Diagnostic criteria and management of metabolic syndrome: Evolution overtime // Gac Med Caracas. %u2013 2020. %u2013 Vol. 128 (4). %u2013P%u0440. 480%u2013504. %u2013 http://dx.doi.org/10.47307/GMC.2020.128.4.519. Gurcan G., %u015eenol S.H., A Ya%u011fc%u0131o%u011flu E.A. et al. Common side effects and metabolic syndrome due to clozapine: Relationship with the clinical variables and disability // Turkish Journal of Psychiatry. %u2013 2020. %u2013 https://doi.org/10.5080/u2573719. Gurcan G., %u015eenol S.H., A Ya%u011fc%u0131o%u011flu E.A. et al. Common side effects and metabolic syndrome due to clozapine: Relationship with the clinical variables and disability // Turkish Journal of Psychiatry. %u2013 2020. %u2013 https://doi.org/10.5080/u2573720. Jae S.Y., Kunutsor S., Sudhir Kurl S., Laukkanen J.A. Impact of diabetes and hypertension on the heightened risk of sudden cardiac death associated with metabolic syndrome: Interrelationship with cardiorespiratory fitness // CardioMetabolic Syndrome Journal. %u2013 2024. %u2013 Vol. 4 (2). %u2013 Art. 106. %u2013 http://dx.doi.org/10.51789/cmsj.2024.4.e1220. Jae S.Y., Kunutsor S., Sudhir Kurl S., Laukkanen J.A. Impact of diabetes and hypertension on the heightened risk of sudden cardiac death associated with metabolic syndrome: Interrelationship with cardiorespiratory fitness // CardioMetabolic Syndrome Journal. %u2013 2024. %u2013 Vol. 4 (2). %u2013 Art. 106. %u2013 http://dx.doi.org/10.51789/cmsj.2024.4.e1221. Dickerson F., Khan S., Origoni A. et al. Risk factors for natural cause mortality in schizophrenia // JAMA Netw Open. %u2013 2024. %u2013 Vol. 7 (9). %u2013 e2432401. %u2013 https://doi.org/10.1001/jamanetworkopen.2024.3240121. Dickerson F., Khan S., Origoni A. et al. Risk factors for natural cause mortality in schizophrenia // JAMA Netw Open. %u2013 2024. %u2013 Vol. 7 (9). %u2013 e2432401. %u2013 https://doi.org/10.1001/jamanetworkopen.2024.3240122. Vasudev K., Choi Y.H., Norman R. et al. Genetic determinants of clozapine-induced metabolic side effects // The Canadian Journal of Psychiatry. %u2013 2017. %u2013 Vol. 62 (2). %u2013P%u0440. 138%u2013149. %u2013 https://doi.org/10.1177/0706743716670128.22. Vasudev K., Choi Y.H., Norman R. et al. Genetic determinants of clozapine-induced metabolic side effects // The Canadian Journal of Psychiatry. %u2013 2017. %u2013 Vol. 62 (2). %u2013P%u0440. 138%u2013149. %u2013 https://doi.org/10.1177/0706743716670128.23. Brennan M.D. Pharmacogenetics of second-generation antipsychotics // Pharmacogenomics. 2014. %u2013 Vol. 15 (6). %u2013 P%u0440. 869%u2013884. %u2013 https://doi.org/10.2217/pgs.14.5023. Brennan M.D. Pharmacogenetics of second-generation antipsychotics // Pharmacogenomics. 2014. %u2013 Vol. 15 (6). %u2013 P%u0440. 869%u2013884. %u2013 https://doi.org/10.2217/pgs.14.5024. Jin H., Meyer J.M., Mudaliar S., Jeste D.V. Impact of atypical antipsychotic therapy on leptin, ghrelin, and adiponectin // Schizophr Res. %u2013 2008. %u2013 Vol. 100 (1%u20133). %u2013 P%u0440. 70%u201385. %u2013 https://doi.org/10.1016/j.schres.2007.11.02624. Jin H., Meyer J.M., Mudaliar S., Jeste D.V. Impact of atypical antipsychotic therapy on leptin, ghrelin, and adiponectin // Schizophr Res. %u2013 2008. %u2013 Vol. 100 (1%u20133). %u2013 P%u0440. 70%u201385. %u2013 https://doi.org/10.1016/j.schres.2007.11.02625. De Luca V., Mueller D.J., de Bartolomeis A., Kennedy J.L. Association of the HTR2C gene and antipsychotic induced weight gain: A meta-analysis // Int J Neuropsychopharmacol. %u2013 2007. %u2013 Vol. 10 (05). %u2013 https://doi.org/10.1017/s146114570700754725. De Luca V., Mueller D.J., de Bartolomeis A., Kennedy J.L. Association of the HTR2C gene and antipsychotic induced weight gain: A meta-analysis // Int J Neuropsychopharmacol. %u2013 2007. %u2013 Vol. 10 (05). %u2013 https://doi.org/10.1017/s146114570700754726. Sicard M.N., Zai C.C., Tiwari A.K. et al. Polymorphisms of the HTR2C gene and antipsychotic-induced weight gain: An update and meta-analysis // Pharmacogenomics. %u2013 2010. %u2013 Vol. 11 (11). %u2013 P%u0440. 1561%u20131571. %u2013 https://doi.org/10.2217/pgs.10.12326. Sicard M.N., Zai C.C., Tiwari A.K. et al. Polymorphisms of the HTR2C gene and antipsychotic-induced weight gain: An update and meta-analysis // Pharmacogenomics. %u2013 2010. %u2013 Vol. 11 (11). %u2013 P%u0440. 1561%u20131571. %u2013 https://doi.org/10.2217/pgs.10.12327. Miller D.D., Ellingrod V.L., Holman T.L. et al. Clozapine-induced weight gain associated with the 5HT2C receptor %u2212759C/T polymorphism // American Journal of Medical Genetics Part B: Neuropsychiatric Genetics. %u2013 2005. %u2013 Vol. 133B (1). %u2013 P%u0440. 97%u2013100. %u2013 https://doi.org/10.1002/ajmg.b.3011527. Miller D.D., Ellingrod V.L., Holman T.L. et al. Clozapine-induced weight gain associated with the 5HT2C receptor %u2212759C/T polymorphism // American Journal of Medical Genetics Part B: Neuropsychiatric Genetics. %u2013 2005. %u2013 Vol. 133B (1). %u2013 P%u0440. 97%u2013100. %u2013 https://doi.org/10.1002/ajmg.b.3011528. Arranz M.J., Rivera M., Munro J.C. Pharmacogenetics of response to antipsychotics in patients with schizophrenia // CNS Drugs. %u2013 2011. %u2013 Vol. 25 (11). %u2013 P%u0440. 933%u2013969. %u2013 https://doi.org/10.2165/11595380-000000000-0000028. Arranz M.J., Rivera M., Munro J.C. Pharmacogenetics of response to antipsychotics in patients with schizophrenia // CNS Drugs. %u2013 2011. %u2013 Vol. 25 (11). %u2013 P%u0440. 933%u2013969. %u2013 https://doi.org/10.2165/11595380-000000000-0000029. Basile V.S., Masellis M., McIntyre R. S. et al. Genetic dissection of atypical antipsychoticinduced weight gain: Novel preliminary data on the pharmacogenetic puzzle // J Clin Psychiatry. %u2013 2001. %u2013 Vol. 62, suppl. 2. %u2013 P%u0440. 45%u201366.29. Basile V.S., Masellis M., McIntyre R. S. et al. Genetic dissection of atypical antipsychoticinduced weight gain: Novel preliminary data on the pharmacogenetic puzzle // J Clin Psychiatry. %u2013 2001. %u2013 Vol. 62, suppl. 2. %u2013 P%u0440. 45%u201366.30. Piatkov I., Caetano D., Assur Y. et al. ABCB1 and ABCC1 single-nucleotide polymorphisms in patients treated with clozapine // Pharmgenomics Pers Med. %u2013 2017. %u2013 Vol. 10. %u2013P%u0440. 235%u2013242. %u2013 https://doi.org/10.2147/pgpm.s14231430. Piatkov I., Caetano D., Assur Y. et al. ABCB1 and ABCC1 single-nucleotide polymorphisms in patients treated with clozapine // Pharmgenomics Pers Med. %u2013 2017. %u2013 Vol. 10. %u2013P%u0440. 235%u2013242. %u2013 https://doi.org/10.2147/pgpm.s14231431. Melkersson K.I., Scordo M.G., Gunes A., Dahl M.-L. Impact of CYP1A2 and CYP2D6 polymorphisms on drug metabolism and on insulin and lipid elevations and insulin resistance in clozapine-treated patients // J Clin Psychiatry. %u2013 2007. %u2013 Vol. 68 (05). %u2013 P%u0440. 697%u2013704. %u2013 https://doi.org/10.4088/jcp.v68n050631. Melkersson K.I., Scordo M.G., Gunes A., Dahl M.-L. Impact of CYP1A2 and CYP2D6 polymorphisms on drug metabolism and on insulin and lipid elevations and insulin resistance in clozapine-treated patients // J Clin Psychiatry. %u2013 2007. %u2013 Vol. 68 (05). %u2013 P%u0440. 697%u2013704. %u2013 https://doi.org/10.4088/jcp.v68n050632. Landi M.T., Sinha R., Lang N.P., Kadlubar F.F. Human cytochrome P4501A2 // IARC SciPubl. %u2013 1999. %u2013 No. 148. %u2013 P%u0440. 173%u2013195.32. Landi M.T., Sinha R., Lang N.P., Kadlubar F.F. Human cytochrome P4501A2 // IARC SciPubl. %u2013 1999. %u2013 No. 148. %u2013 P%u0440. 173%u2013195.33. Guengerich F.P., Distlerath L.M., Reilly P.E. et al. Human-liver cytochromes P-450 involved in polymorphisms of drug oxidation // Xenobiotica. %u2013 1986. %u2013 Vol. 16 (5). %u2013 P%u0440. 367%u2013378. %u2013 https://doi.org/10.3109/0049825860905024533. Guengerich F.P., Distlerath L.M., Reilly P.E. et al. Human-liver cytochromes P-450 involved in polymorphisms of drug oxidation // Xenobiotica. %u2013 1986. %u2013 Vol. 16 (5). %u2013 P%u0440. 367%u2013378. %u2013 https://doi.org/10.3109/0049825860905024534. Ruan C.-J., de Leon J. Is there a future for CYP1A2 Pharmacogenetics in the optimal dosing of clozapine? // Pharmacogenomics. %u2013 2020. %u2013 Vol. 21 (6). %u2013 P%u0440. 369%u2013373. %u2013https://doi.org/10.2217/pgs-2020-001534. Ruan C.-J., de Leon J. Is there a future for CYP1A2 Pharmacogenetics in the optimal dosing of clozapine? // Pharmacogenomics. %u2013 2020. %u2013 Vol. 21 (6). %u2013 P%u0440. 369%u2013373. %u2013https://doi.org/10.2217/pgs-2020-001535. Bertilsson L., Carrillo J.A., Dahl M.L. et al. Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test // Br J Clin Pharmacol. %u2013 1994. %u2013 Vol. 38 (5). %u2013P%u0440. 471%u2013473. %u2013 https://doi.org/10.1111/j.1365-2125.1994.tb04385.x35. Bertilsson L., Carrillo J.A., Dahl M.L. et al. Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test // Br J Clin Pharmacol. %u2013 1994. %u2013 Vol. 38 (5). %u2013P%u0440. 471%u2013473. %u2013 https://doi.org/10.1111/j.1365-2125.1994.tb04385.x